Competitive binding of a monoclonal antibody SZ-21 with anti-PLA1 antibodies and its potential for clinical application
- PMID: 1383923
Competitive binding of a monoclonal antibody SZ-21 with anti-PLA1 antibodies and its potential for clinical application
Abstract
Both intact IgG and Fab fragments of a monoclonal antibody SZ-21, directed against platelet glycoprotein (GP) IIIa, inhibited binding of anti-PLA1 antibodies to PLA1-positive platelets in a dose dependent manner. Conversely, the binding capacity of the platelets for SZ-21 was decreased in the presence of anti-PLA1 antibodies. In Western blots, the determinant for SZ-21 was present on GPIIIa from either PLA1 or PLA2 homozygotes, but SZ-21 did not affect the interaction of anti-Yukb alloantibodies with their target antigen on GPIIIa. These results suggest that SZ-21 reacts with an epitope on the GPIIIa molecule very close to but not identical with that for anti-PLA1. The existence of PLA1-reactive alloantibodies in serum could be demonstrated by their competitive effect on the binding of SZ-21.
Similar articles
-
Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa.Blood. 1996 Nov 1;88(9):3601-7. Blood. 1996. PMID: 8896429
-
[Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].Biokhimiia. 1996 Mar;61(3):412-28. Biokhimiia. 1996. PMID: 8724599 Russian.
-
A monoclonal antibody (LK-4) which differentiates PLA1 from PLA2 platelet extracts but not intact platelets.Thromb Res. 1992 May 15;66(4):309-20. doi: 10.1016/0049-3848(92)90281-e. Thromb Res. 1992. PMID: 1384161
-
Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets.Thromb Haemost. 1998 Jan;79(1):177-85. Thromb Haemost. 1998. PMID: 9459345 Clinical Trial.
-
Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response.Blood. 1995 Jun 1;85(11):3028-33. Blood. 1995. PMID: 7756638
Cited by
-
Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia.Transfusion. 2009 Feb;49(2):265-70. doi: 10.1111/j.1537-2995.2008.01972.x. Epub 2008 Nov 4. Transfusion. 2009. PMID: 19000229 Free PMC article.
-
Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.Blood Adv. 2021 Sep 28;5(18):3552-3562. doi: 10.1182/bloodadvances.2021004371. Blood Adv. 2021. PMID: 34470046 Free PMC article.
-
Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients.J Transl Med. 2017 Oct 23;15(1):214. doi: 10.1186/s12967-017-1317-2. J Transl Med. 2017. PMID: 29061180 Free PMC article.